Backgrounds/Aims: Discovery of new prognostic factors for cases in which the pancreatic cancer scoring and staging system does not result in a clear definition is imperative. We examined the role of Human AlkB homolog H5 (ALKBH5) as a prognostic marker for pancreatic cancer. Methods: Patient data were extracted from the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). The prognostic value of ALKBH5 was confirmed via analysis of ALKBH5 and other clinical factors, such as age, sex, and stage, using the time-dependent area under the curve (AUC) of Uno's C-index, the AUC value of the receiver operating characteristics (ROC) at three years, the Kaplan-Meier survival curve, and multivariate analysis. Results: ALKBH5 showed excellent prognosis prediction in comparison with existing markers in the two independent cohorts (n=262). Kaplan-Meier survival analysis showed that ALKBH5 expression was positively associated with overall survival (log-rank test, ICGC, p=0.001; TCGA, p=0.01). 
INTRODUCTION
Pancreatic neoplasms are one of the few cancers with a mortality rate approaching 100%. 1 Furthermore, only 15-20% of patients are diagnosed during early stages because of nonspecific symptoms and approximately 50% present with distant metastasis at the time of diagnosis. 2, 3 As the etiology and screening test for this highly lethal
disease have yet to be well defined, it is important to identify genetic factors that contribute to the development of this cancer.
4 N 6 -methyladenosine (m 6 A) is the most prevalent epitranscriptomic modification of the mRNA of higher eukaryotes. 5, 6 Human AlkB homolog H5 (ALKBH5) is a demethylase that oxidatively reverses several mRNAs, and significantly affects mRNA export and RNA metabolism, as well as the assembly of mRNA processing factors in nuclear speckles. This modification plays an essential role in the regulation of mRNA translation and RNA metabolism. Evidence strongly suggests that epigenetic alterations, especially methylation induce tumorigenesis-associated cellular changes, suggesting the role of oncogenic mechanisms beyond DNA mutations in cancer. [6] [7] [8] [9] The methylation of related genes and mRNA has been strongly linked to the development and progression of pancreatic cancer. The regulation of the expression of oncogenic and tumor suppressor genes by demethylation or methylation mechanisms plays a significant role in identi- Based on the function of ALKBH5 as an mRNA methylation regulator, we hypothesized that ALKBH5 influences the survival of patients with pancreatic cancer.
Therefore, we examined the role of ALKBH5 as a novel prognostic marker complementing the current deficient staging and scoring systems.
MATERIALS AND METHODS

Data acquisition and characteristics
Primary and processed data, including mRNA expression and clinical information, were downloaded from
The Cancer Genome Atlas (TCGA) and International
Cancer Genome Consortium (ICGC) in October 2017. [10] [11] [12] These processes were performed using the cgdsr package of R software version 3. 
Survival analysis
Survival analyses were performed to predict the overall survival (OS) using three methods: [1] Kaplan-Meier survival curves to evaluate the accuracy of the discrimination, [2] Uno's C-index for the time-dependent area under the curve (AUC) analysis, and [3] AUC values in receiver operating characteristics (ROC) at three years.
These analyses were performed using R packages survival and survAUC. C-indices and AUC values ≥0.6 were considered acceptable for survival predictions. Using
Kaplan-Meier analyses, we determined the optimal cutoff value with the maximal Uno's C-index by 5-fold cross-validation. We used univariate and multivariate Cox regression to compare the effect of ALKBH5 on prognosis along with other clinical variables. Statistical analyses were performed using R software.
RESULTS
Patient distribution
In total, 172 TCGA and 90 ICGC patients were included in this study. Of the 172 patients in the TCGA 
ALKBH5 survival curve
To identify the discriminatory power of ALKBH5 as a categorical variable, we analyzed Kaplan-Meier curves for ALKBH5 gene expression and survival. High expression of ALKBH5 was a significant predictor of overall survival in the TCGA and ICGC cohorts (p=0.01 and p=0.001, Fig. 2A, D) . The prognostic value was further confirmed using multivariate analysis (ICGC, p=0.0123; TCGA, p ＜0.001, Table 2 ).
ALKBH5 C-index and AUC values
To evaluate the prognostic value of ALKBH5, we com- Administration. 17, 18 The poor prognosis of pancreatic cancer is attributed to its late presentation and lack of accurate predictive biomarkers for early diagnosis and prognosis. 19 In the current study, ALKBH5 facilitated the classification of patients into two risk groups in two independent cohorts. In addition, it also scored higher C-in- With increasing evidence suggesting the role of epigenetic alterations especially methylation in triggering tumorigenesis-associated cellular changes, the field of cancer research has evolved to incorporate oncogenic mechanisms beyond DNA mutations.In particular, the importance of m6A in mRNA has attracted attention due to its role in epitranscriptomic modification of cellular differentiation and pluripotency. However, the effect of modification of m6A mRNA on the complex process of tu-morigenesis is unclear.
In conclusion, we found that the survival rate of patients with pancreatic cancer was enhanced under high ALKBH5 expression. Despite the unclear mechanism of action of ALKBH5 in tumorigenesis, it has been suggested that ALKBH5 may have a positive effect on the development and progression of pancreatic cancer. We believe that these findings will contribute to the study of RNA methylation in pancreatic cancer.
